PLA2G6-associated Dystonia-Parkinsonism: Case Report and Literature Review by Karkheiran, Siamak et al.
Case Reports
PLA2G6-associated Dystonia–Parkinsonism: Case Report and Literature Review
Siamak Karkheiran
1
, Gholam Ali Shahidi
1




1Movement Disorders Clinic, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran, 2Department of Neurology, James J. Peters Veterans
Affairs Medical Center, Bronx, NY, USA, 3Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 4Department of Psychiatry,
Icahn School of Medicine at Mount Sinai, New York, NY, USA, 5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New
York, NY, USA, 6The Friedman Brain and The Mindich Child Health and Development Institutes, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Abstract
Background: Phospholipase-associated neurodegeneration (PLAN) caused by PLA2G6 mutations is a recessively inherited disorder with three known phenotypes:
the typical infantile onset neuroaxonal dystrophy (INAD); an atypical later onset form (atypical NAD); and the more recently recognized young-onset dystonia–
parkinsonism (PLAN-DP).
Case Report: We report the clinical, radiological, and genetic findings of a young Pakistani male with PLAN-DP. We review 11 previously published case reports
cited in PubMed, and summarize the demographic, clinical, genetic, and radiological data of the 23 patients described in those articles.
Discussion: PLAN-DP presents with diverse motor, autonomic, and neuropsychiatric features and should be considered in the differential diagnosis of patients
with young-onset neurodegenerative disorders.
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Introduction
The first description of infantile neuroaxonal dystrophy (INAD) was
published in 1952 by the German neurologist Franz Seitelberger, who
described two siblings presenting with psychomotor delay in infancy
followed by progressive neuroregression, leading to severe disability
and death in the first decade of life.1 Widespread distal axonal swelling
with spheroid bodies—the histological feature known as neuroaxonal
dystrophy (NAD)—was the pathological hallmark at autopsy of
Seitelberger’s patients and of other cases described later.1–3 Twenty-
seven years after Seitelberger’s report, Aicardi and Castelein2 reported
eight new patients, reviewed 77 previously published cases, and
proposed the first criteria for INAD. In 1999, Nardocci et al.4 described
13 patients and added a new phenotype, atypical NAD, with a more
protracted course and cerebellar signs as distinctive clinical findings.
In 2006 mutations in PLA2G6 were identified in patients with
INAD, and also in a group of patients with neurodegeneration with
brain iron accumulation (NBIA) who did not have mutations in PANK2
(i.e. did not have pantothenate kinase-associated neurodegeneration
[PKAN]).5,6 Subsequently, all phenotypes have been termed phos-
pholipase-associated neurodegeneration (PLAN).7 In 2009, Paisa´n-
Ruiz et al.8 broadened the phenotypic spectrum of PLAN by
identifying PLA2G6 mutations in patients with early-onset levodopa-
responsive dystonia–parkinsonism associated with cognitive decline,
oculomotor abnormalities, psychiatric features, and pyramidal signs.
Subsequently, a range of phenotypes has been reported, from pure
Parkinsonism to severe generalized dystonia.9–18 In this article, we
report a new patient with PLA2G6-associated dystonia–parkinsonism
(PLAN-DP) and review the literature.
Case report
A 20-year-old Pakistani male was born to first-degree-relative
parents. He was asymptomatic until age 14 years, when he developed
blepharospasm and jaw-opening dystonia, followed by foot dragging
and foot dystonia and handwriting deterioration. Over the next 4 years
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his symptoms progressed to generalized dystonia. At the age of 19, he
was bradykinetic with hypomimia, jaw-opening dystonia, blepharos-
pasm, facial and upper extremity myoclonic jerks, and dysarthria
(Video 1). Ocular motility was normal. Strength was normal in all
extremities. Muscle tone and deep tendon reflexes were increased
throughout with right ankle clonus, but plantar reflexes were
downgoing. Gait was short-stepped and spastic. He could not walk
unassisted because of foot dystonia and severely impaired postural
reflexes. Sensory and cerebellar examination was normal. The
Wechsler Adult Intelligent Test revised score was 88 (verbal, 101;
performance, 74). At age 20, he experienced a generalized seizure and
an electroencephalogram demonstrated right frontotemporal slowing.
No further seizures occurred on treatment with sodium valproate.
Several drugs, including levodopa (maximum dose 800 mg/day),
amantadine (maximum dose 400 mg/day), dopamine agonists, antic-
holinergics, baclofen, tizanidine, and diazepam (maximum doses of the
medications are not known), were tried without beneficial effects.
All laboratory tests including serum biochemistry, liver and thyroid
function tests, serum copper and ceruloplasmin levels, and cerebrospinal
fluid analysis were normal. Kayser–Fleischer rings were not detected.
Brain magnetic resonance imaging (MRI) (Figure 1) showed mild
generalized cortical and cerebellar atrophy, a vertically oriented
splenium, and claval hypertrophy. T2* sequences demonstrated iron
deposition in the basal ganglia, most prominently in the globus pallidus.
Direct sequencing of the PLA2G6 gene revealed a homozygous
c.2222G.A mutation resulting in a p.R741Q transition. The
p.R741Q mutation was previously described as pathogenic
(rs121908686)8 and is present in the ExAC database with very low
frequency (0.0002277). It is only reported in the South Asian population
(four out of 7,854) (http://exac.broadinstitute.org/variant/22-
38508565-C-T), and all cases reported by us share a common haplotype
of 769.36 kbp flanked by single nucleotide polymorphisms rs6519064
(36,171,965 bp) and rs2235265 (36,941,833 bp), likely suggesting a
common ancestor between all mutation carriers.19
We searched the PubMed database using the following terms:
PLA2G6 parkinsonism, PLA2G6 dystonia, PLAN, and PLA2G6
dystonia–parkinsonism. We found 11 articles describing patients with
young- or adult-onset PLAN-DP, reporting 23 patients from 16
pedigrees.8–18
The youngest age of disease onset was 4 years old and the oldest was
37, and all had motor and/or neuropsychiatric features prior to age
40. Parkinsonism (rigidity and bradykinesia) was universally present.
Rest tremor was found in 16 out of 24 patients.8–13,15,18 Eighteen
patients had dystonia with variable severity, distribution, and time of
appearance during the disease course.8–10,12–17 A summary of the
demographic and sensory/motor symptoms is shown in (Table 1). The
patients, ethnicity and mutations are shown in (Table 2).
Neuropsychiatric disorders such as depression, psychosis, cognitive
decline, dementia, personality changes, behavioral disorders, and
anxiety and obsessive compulsive disorders have all been described
and can be presenting symptoms (Table 3).
Brain MRI was performed in all patients (Table 4). Cerebral
atrophy was found in 13 patients (54%)8,9,11,13,15,17 and cerebellar
atrophy in seven (29%).10,15,16 Other patients were either normal or
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Figure 1. Brain Magnetic Resonance Imaging of Patient with PLA2G6-
associated Dystonia–Parkinsonism. (A,B) Axial fluid-attenuated inversion
recovery images show frontotemporal atrophy with widened temporal horns of
lateral ventricles (arrow in A) and lateral fissure (arrow in B). (C) Mid-sagittal
T1 image shows vertically oriented splenium (arrow) and apparent claval
hypertrophy (arrowhead). Mild cerebellar vermis atrophy is also visible. (D) SWI
demonstrates bilateral hypointensity in the globus pallidus due to iron deposition
(arrow).
Video 1. PLAN-DP case report. The video shows generalized bradykinesia,
masked facies, blepharospasm, jaw-opening dystonia and right ankle clonus. The
gait is limited by leg spasticity and dystonia, and balance is severely impaired.
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imaging was not reported in detail. Iron was found in only eight
patients (33%):10,11,14,16,17 four on gradient echo (GRE) or suscept-
ibility-weighted imaging (SWI), two on T2, and two on both T2 and
GRE. Iron was deposited in the globus pallidus10 and substantia
nigra,17 or both.11,16
Functional imaging studies were carried out in some subjects. Single
positron emission computed tomography in one patient showed frontal
hypoperfusion compatible with the patient’s clinical features of
frontotemporal dementia.11 In another patient with dementia and
ataxia, fludeoxyglucose positron emission tomography (PET) demon-
strated frontal and cerebellar hypometabolism, corresponding to
cerebral and cerebellar atrophy seen on brain MRI.15
Reduced dopamine transporter (DAT) labeling was seen in all 10
patients studied using this methodology.8,12,14–18 In order to examine
pre- and post-synaptic dopaminergic function, one patient received
four different tracers: PET with [18]F-6-flouro-L-dopa, [11]C-
dihydrotetrabenazine, and [11]C-d-thereo-methylphenidate (DAT
marker) disclosed reduced presynaptic dopaminergic uptake, while
[11]C-raclopride showed increased post-synaptic dopaminergic recep-
tor labeling. Labeling with all tracers was identical to that seen in
idiopathic Parkinson’s disease (IPD).14
The only mutation examined for its effects upon the catalytic
function of PLA2G6 was the p.D331Y mutation. The p.D331Y mutant
cells showed a 70% reduction in PLA2G6 catalytic function when
compared with their wild-type counterparts.12
Discussion
We report a new case of adult-onset PLAN with dystonia,
Parkinsonism, and epilepsy. On review of the literature there is notable
heterogeneity in clinical presentation and phenotype. Parkinsonism
(bradykinesia and rigidity) appeared uniformly during the disease
course; however, the initial presentation varied greatly, and neurop-
sychological symptoms such as depression, psychosis, and cognitive
decline preceded the motor problems on several occasions (Table 1,
Table 4).10,13,14 In a couple of cases, onset was in early childhood with
non-specific signs of motor slowness or speech problems.8,10,13,15
Autonomic dysfunction, specifically urinary or bowel dysfunction,
has been observed in a number of cases, although not the current case,
and may be an important diagnostic clue as this feature is not typical of
most other neurodegenerative disorders affecting this age group. The
pathophysiology of this symptom is unknown but is likely related to
spinal cord neurodegeneration.
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Table 2. Mutations and Ethnicity of Patients with PLA2G6 Associated Dystonia–Parkinsonism
Report Patients Ethnicity/Consanguinity Mutation Result
Paisa´n-Ruiz et al.8 Family 1 Indian/+1 c.2222G.A p.R741Q
Paisa´n-Ruiz et al.8 Family 2 Pakistani/+ c.2239C.T p.R747W
Sina et al.9 One family Iranian/+ c.1894C.T p.R632W
Bower et al.10 One family European/– c.4C.A/Del Ex 3 p.Q2K/
pL71_S142del
Yushino et al.11 Patient A Japanese/– c.216C.A/c.1904G.A p.F72L/p.R635Q
Yushino et al.11 Patients B1,B2 Japanese/– c.1354C.T/c.1904G.A p.Q452X/p.R635Q
Shi et al.12 One patient Chinese/+ c.991G.T p.D331Y
Virmani et al.13 One family Indian/+ c.2222G.A p.R741Q
Agarwal et al.14 One family Scandinavian/– c.238G.A p.A80T
Lu et al.15 Two families Han Chinese/– c.991G.T/c.1077G.A p.D331Y/p.M358IfsX
Lu et al.15 One family Han Chinese/+ c.991G.T p.D331Y
Kim et al.16 One family Korean/– c.1039G.A/c.1670C.T p.G347R/p.S557L
Malaguti et al.17 One family Italian/– c.1547C.T p.A516W
Xie et al.18 Two families Chinese/+ c.991G.T p.D331Y
This work One Family Pakistani/+ c.2222G.A p.R741Q
+, Consanguineous Parents; –, Non-consanguineous Parents.
1Thirteen patients were the result of consanguineous marriages.
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There is no evidence of a genotype–phenotype correlation, apart
from possibly in patients with pure Parkinsonism and the p.D331Y
mutation.12,15,18 The similarity between these four patients from
different families, specifically the presence of Parkinsonism without
dystonia, prompted the authors to propose a correlation between this
genotype and phenotype;18 however, more cases are required to
support their hypothesis.
In our patient and in the previously reported cases, most MRI
images showed rather non-specific changes. Iron accumulation was
found in only eight patients (33%), which is less than what is reported
in INAD (40–50%).7,20 In four of the PLAN-DP cases, iron was
detected on GRE/SWI sequences, emphasizing the importance of
these techniques in the appropriate situation. The process of iron
deposition in PLAN-DP is not yet clear. In INAD, iron accumulates
over time,7 but there has been neither a prospective study in PLAN-
DP imaging nor sequential imaging using a unified protocol, thus this
issue requires further study. In addition to the finding of iron
deposition, other helpful imaging findings are a smooth and vertically
oriented posterior corpus callosum, and apparent claval hypertrophy.
Although these structural alterations have been previously described in
patients with INAD and atypical NAD,7,20 they were present in the
current patient (Figure 1) and in those reported by Lu et al.15 and
Malaguti et al.17
PET imaging demonstrated a dysfunctional presynaptic dopami-
nergic system and increased post-synaptic uptake in patterns similar to
those in IPD, thus functional imaging techniques are not helpful in
differentiating PLAN-DP from IPD.
In addition to the similarities on functional imaging and reports of
an early response to levodopa,8,9,11–18 the pathology of PLAN-DP
resembles that of IPD. In a post-mortem study, Paisa´n-Ruiz et al.21
examined brains of two PLAN phenotypes (INAD n54; PLAN-DP
n53) and found a-synuclein pathology with Lewy bodies and Lewy
neurites in all cases, and iron deposition in two PLAN-DP brain
sample and one INAD brain sample. Lewy body distribution varied,
from being restricted to the medulla (Braak stage 1)22 to extensive
spread throughout the brain including the neocortex (Braak stage 6).22
This identical a-synuclein pathology suggests a possible final common
pathway in the pathogenesis of PLAN and IPD, whether or not
Parkinsonism or dystonia is present. In this study, extensive tau
pathology with neurofibrillary tangles and neuropil threads was found
in four cases, suggesting a link between the PLA2G6 mutation and tau
hyperphosphorylation and deposition.
The protein product of PLA2G6, phospholipase-A2 group-VI
(iPLA2-IVA), is an enzyme that is involved in the metabolism of
glycerophospholipids,23 phospholipid remodeling, arachidonic acid
release, synthesis of prostaglandins and leukotrienes, and apoptosis.24
It plays an important role in inner mitochondrial membrane
homeostasis,25 in particular in maintaining normal functioning of
cardiolipin, the signature phospholipid of mitochondria,26,27 which
tethers electron transfer chain molecules to inner mitochondrial
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Table 3. Summary of Neuropsychiatric Disorders
Reference Patient number (if appropriate): Symptoms
Paisa´n-Ruiz et al.8 P1: Cognitive decline, depression
P2: Cognitive decline, frontal execution dysfunction, personality change with aggression
Sina et al.9 Cognitive decline
Bower et al.10 P1: Depression
P2: Behavioral difficulties, delusions, and paranoia
Yoshino et al.11 A: Frontotemporal dementia, depression, personality/behavioral changes, disordered social conduct,
and apathy
B1, B2: Dementia
Virmani et al.13 P1: Depression with psychosis, pseudobulbar affect
P2: Depression and cognitive decline
Agarwal et al.14 Anxiety, obsessive compulsive disorder, depression, frontal executive dysfunction
Lu et al.15 Dementia
Kim et al.16 Low IQ
Malaguti et al.17 Dysphoric and anosognosic behavior, executive dysfunction such as impulsive behavior, reduced
strategic planning, inability to use environmental feedback to shift cognitive sets, reduced mental
flexibility, and mild memory impairment
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membrane.28 iPLA2-VIA also plays a role in capacitative Ca entry, a
mechanism that is important in intracellular Ca2+ homeostasis.29
Dysfunction of mitochondrial and Ca2+ homeostasis may be key
elements in the pathophysiology of PLAN, possibly similar to those
which have been postulated in IPD.30–32
A dramatic reduction in catalytic activity of the p.D331Y mutated
enzyme was reported.12 However, other authors found that INAD-
producing mutations severely impaired iPLA2-IVA enzyme function,
while mutations causing PLAN-DP either did not change enzyme
activity nor increased it.33 To explain this discrepancy, we believe that
other genetic factors rather than just catalytic activity of iPLA2-IVA
play a substantial role in determining phenotype. A report of two
siblings with identical genotype and different phenotypes supports this
idea.16
In conclusion, PLAN-DP is characterized by remarkable hetero-
geneity in disease presentation and course. Our understanding of this
disorder and its phenotypic spectrum continues to evolve and expand
with the ongoing publication of case reports and series. At present, it
appears that there is no clear clinical scenario typical of PLAN-DP.
Basal ganglia iron deposition is helpful when present, and should be
sought with the appropriate MRI sequences, but if absent does not
eliminate the diagnosis. This disorder should be considered on the list
of differential diagnoses for a wide range of complex, young-onset
neurodegenerative disorders.
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